Predictive factors for prolonged sick leave in breast cancer patients treated with adjuvant therapies: a retrospective registry study

Authors

  • Riikka-Leena Leskelä a Nordic Healthcare Group, Helsinki, Finland
  • Ira Haavisto a Nordic Healthcare Group, Helsinki, Finland; b Hanken School of Economics, Helsinki, Finland
  • Paula Pennanen a Nordic Healthcare Group, Helsinki, Finland
  • Mari Lahelma a Nordic Healthcare Group, Helsinki, Finland
  • Johanna Mattson c Helsinki University Hospital Comprehensive Cancer Canter, University of Helsinki, Helsinki, Finland
  • Paula Poikonen-Saksela c Helsinki University Hospital Comprehensive Cancer Canter, University of Helsinki, Helsinki, Finland

DOI:

https://doi.org/10.1080/0284186X.2023.2254483

Keywords:

Breast cancer, treatment, prolonged sick-leave, return-to-work, predictive, registry study

Abstract

Background

Being able to work during and after breast cancer treatments is important for patients to have a sense of normalcy, financial security, and improved quality of life, and for society due to the economic burden of sick leave. Factors influencing the length of sick leave can be sociodemographic factors, workplace adaptations, recurrences, symptoms, and type of treatment. The aim of this study is to analyse factors associated with prolonged sick leave after adjuvant breast cancer treatments.

Methods

The population of this registry study consists of 1333 early breast cancer patients diagnosed and treated in Helsinki University Hospital between 2016 and 2018. Data on patient demographics, disease characteristics, treatment, and healthcare resource utilization were obtained from Helsinki University Hospital and data on income level and sick leave were obtained from Kela sickness benefits registry. Prolonged sick leave was determined as the patient accumulating 30 or more reimbursed sick leave days during a 60-day follow-up period after the end of active oncological treatment. Univariate analysis and multivariate analysis were conducted.

Results

A total of 26% of the patients in this study were on sick leave for 30 or more days after the active treatments ended. Study findings show that chemotherapy, triple-negative breast cancer, reconstructive surgery, amount of outpatient visits, and income are associated with prolonged sick leave. Independent predictors of prolonged sick leave were treatment line, number of outpatient contacts, reconstruction, and triple-negative breast cancer.

Conclusions

Our study shows that prolonged sick leave affects a substantial number of working-age women with early breast cancer. Independent predictors for prolonged sick leave were all treatment-related. Targeted support for treatment-related side-effects already during the treatment period could lead to better recovery and earlier return to work.

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2023-10-03

How to Cite

Leskelä, R.-L. ., Haavisto, I., Pennanen, P., Lahelma, M., Mattson, J., & Poikonen-Saksela, P. (2023). Predictive factors for prolonged sick leave in breast cancer patients treated with adjuvant therapies: a retrospective registry study. Acta Oncologica, 62(10), 1331–1337. https://doi.org/10.1080/0284186X.2023.2254483